Skip to Content
Morningstar

Pfizer Inc PFE

Morningstar Rating
Unlock
Stock XNYS Rating as of
$27.83 −0.39 (1.38%)
View Full Chart
As of Delayed Price Pre-Open: $27.88 +0.05
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

GSK, Pfizer, and Moderna: New RSV Vaccine Guidance Shrinks, but Long-Term Potential Remains

Damien Conover

The Centers for Disease Control and Prevention refined its RSV vaccine recommendations to adults aged 75 and older as well as those 60 to 74 years old at higher risk for RSV disease, which is a smaller group than the initial guidance for adults aged 60 and older. However, we don’t expect a major impact on the long-term potential for the RSV vaccines from GSK, Pfizer, and Moderna. We are maintaining our fair value estimates and moat ratings for the firms.

Read Full Report

Price vs Fair Value

View History
PFE is trading at a 859% premium.
Price
$27.83
Fair Value
$16.00
Uncertainty
Medium
1-Star Price
$93.80
5-Star Price
$26.90
Economic Moat
Cjvz
Capital Allocation
Fgdmcwcr

Bulls Say, Bears Say

Bulls

Pfizer's pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.

Bears

Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PFE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$28.22
Day Range
$27.69–28.28
52-Week Range
$25.20–37.80
Bid/Ask
$27.85 / $27.89
Market Cap
$157.70 Bil
Volume/Avg
40,196 / 37.8 Mil

Key Statistics

Price/Earnings (Normalized)
19.42
Price/Sales
2.85
Dividend Yield (Trailing)
5.96%
Dividend Yield (Forward)
6.04%
Total Yield
5.96%

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
88,000
Website
https://www.pfizer.com

Competitors

Valuation

View More
Metric
PFE
LLY
MRK
Price/Earnings (Normalized)
 19.4296.9658.85
Price/Book Value
 1.7163.728.01
Price/Sales
 2.8522.805.29
Price/Cash Flow
 18.3294.7418.62
Price/Earnings
PFE
LLY
MRK

Financial Strength

Metric
PFE
LLY
MRK
Quick Ratio
 0.670.680.68
Current Ratio
 1.051.351.25
Interest Coverage
 −0.2614.113.97
Quick Ratio
PFE
LLY
MRK

Profitability

Metric
PFE
LLY
MRK
Return on Assets (Normalized)
 3.77%11.20%5.22%
Return on Equity (Normalized)
 8.51%57.69%13.56%
Return on Invested Capital (Normalized)
 5.75%20.65%8.29%
Return on Assets
PFE
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
TtvlmblhpvWkqt$816.4 Bil
 Johnson & Johnson
JNJ
QnbhgfzzhKhc$351.4 Bil
 Merck & Co Inc
MRK
NvqgdvvgLhrz$323.5 Bil
 AbbVie Inc
ABBV
RjpgxhcDclb$293.1 Bil
 AstraZeneca PLC ADR
AZN
FlhmsgxcMckt$236.9 Bil
 Roche Holding AG ADR
RHHBY
TthxkfqltZqdjk$222.4 Bil
 Novartis AG ADR
NVS
TbddktjjmRvfnd$217.9 Bil
 Amgen Inc
AMGN
RglfbmzyhGzgly$166.7 Bil
 Sanofi SA ADR
SNY
VvnqfwgwNywn$121.5 Bil

Sponsor Center